Subjects Enrolled in Presept Colorectal Cancer Screening

Epigenomics AG (Frankfurt:ECX), a molecular diagnostics company focusing on the development and commercialization of products for cancer detection based on DNA methylation, has announced the enrollment of the first subjects in the PRESEPT study. "We are excited that our PRESEPT study is now well under way as scheduled. PRESEPT is a unique endeavor: It is one of the largest colorectal cancer screening studies ever, and is the first to prospectively evaluate a molecular marker for blood-based colorectal cancer screening," commented Geert Nygaard, Chief Executive Officer of Epigenomics. "The study will support the imminent clinical validation and commercial launch of our partners' diagnostics tests based on our biomarker and technology. The PRESEPT study is a great leap forward in the realization of our vision of detecting cancers based on DNA methylation patterns with a standard blood test."